Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

Stopped due to lack of enrollment and changes to the sponsor development portfolio

Conditions

• Primary Immune Deficiency Disorders
• Hemophagocytic Lymphohistiocytosis
• Inherited Bone Marrow Failure Syndrome
• Hemoglobinopathies
• Metabolic Disorders

Interventions

• BIOLOGICAL: BPX-501 and Rimiducid

Sponsor

Bellicum Pharmaceuticals